{ "instance": { "hznp-10q_20200331.htm": { "axisCustom": 0, "axisStandard": 38, "contextCount": 318, "dts": { "calculationLink": { "local": [ "hznp-20200331_cal.xml" ] }, "definitionLink": { "local": [ "hznp-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "hznp-10q_20200331.htm" ] }, "labelLink": { "local": [ "hznp-20200331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hznp-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hznp-20200331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 685, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 21, "http://www.horizonoharma.com/20200331": 2, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 29 }, "keyCustom": 78, "keyStandard": 370, "memberCustom": 97, "memberStandard": 47, "nsprefix": "hznp", "nsuri": "http://www.horizonoharma.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Acquisitions, Divestitures and Other Arrangements", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangements", "shortName": "Acquisitions, Divestitures and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Inventories", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Property and Equipment", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Accrued Expenses", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": null }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Accrued Trade Discounts and Rebates", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebates", "shortName": "Accrued Trade Discounts and Rebates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapValuationAllowancesAndReservesTypeAxis_hznpAccruedTradeDiscountsAndRebatesMember_20200101_20200331", "decimals": null, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Segment and Other Information", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformation", "shortName": "Segment and Other Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Fair Value Measurements", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Debt Agreements", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements", "shortName": "Debt Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Lease Obligations", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligations", "shortName": "Lease Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Commitments and Contingencies", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Legal Proceedings", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLegalProceedings", "shortName": "Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Share-Based and Long-Term Incentive Plans", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlans", "shortName": "Share-Based and Long-Term Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Income Taxes", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Subsequent Events", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Net Loss per Share (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Acquisitions, Divestitures and Other Arrangements (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsTables", "shortName": "Acquisitions, Divestitures and Other Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Inventories (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Property and Equipment (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Accrued Trade Discounts and Rebates (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesTables", "shortName": "Accrued Trade Discounts and Rebates (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapValuationAllowancesAndReservesTypeAxis_hznpAccruedTradeDiscountsAndRebatesMember_20200101_20200331", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Segment and Other Information (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationTables", "shortName": "Segment and Other Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Debt Agreements (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTables", "shortName": "Debt Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Lease Obligations (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsTables", "shortName": "Lease Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:SummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "hznp:SummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Share-Based and Long-Term Incentive Plans (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansTables", "shortName": "Share-Based and Long-Term Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Income Taxes (Tables)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Basis of Presentation and Business Overview - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "shortName": "Basis of Presentation and Business Overview - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapQuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis_hznpOutOfPeriodAdjustmentsMember_20200101_20200331", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "hznp:PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Summary of Significant Accounting Policies - Depreciation and Amortization Periods for Property and Equipment (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail", "shortName": "Summary of Significant Accounting Policies - Depreciation and Amortization Periods for Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "hznp:PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Net Loss per Share - Basic and Diluted Net Loss per Share (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetail", "shortName": "Net Loss per Share - Basic and Diluted Net Loss per Share (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Net Loss per Share - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail", "shortName": "Net Loss per Share - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapDebtInstrumentAxis_hznpExchangeableSeniorNotesMember_20200101_20200331", "decimals": "-5", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "shortName": "Acquisitions, Divestitures and Other Arrangements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapBusinessAcquisitionAxis_hznpRiverVisionDevelopmentCorpMember_20170508", "decimals": "INF", "lang": null, "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapDisposalGroupClassificationAxis_us-gaapDisposalGroupNotDiscontinuedOperationsMember_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_hznpMIGERGOTTransactionMember_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Acquisitions, Divestitures and Other Arrangements - Loss on Sale of Assets (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail", "shortName": "Acquisitions, Divestitures and Other Arrangements - Loss on Sale of Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "hznp:AcquisitionsDivestituresAndOtherArrangementsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapDisposalGroupClassificationAxis_us-gaapDisposalGroupNotDiscontinuedOperationsMember_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_hznpMIGERGOTTransactionMember_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Inventories - Components of Inventories (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail", "shortName": "Inventories - Components of Inventories (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "hznp:DeferredTaxChargeOnIntraCompanyProfit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail", "shortName": "Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "hznp:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "hznp:DeferredTaxChargeOnIntraCompanyProfit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Property and Equipment - Property and Equipment (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail", "shortName": "Property and Equipment - Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Property and Equipment - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail", "shortName": "Property and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_srtStatementGeographicalAxis_hznpDeerfieldIllinoisMember_20200201_20200226", "decimals": "-5", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentAdditions", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "shortName": "Goodwill and Intangible Assets - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill for Reportable Segments (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail", "shortName": "Goodwill and Intangible Assets - Schedule of Goodwill for Reportable Segments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapStatementBusinessSegmentsAxis_hznpOrphanMember_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Goodwill and Intangible Assets - Amortizable Intangible Assets (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "shortName": "Goodwill and Intangible Assets - Amortizable Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail", "shortName": "Goodwill and Intangible Assets - Estimated Future Amortization Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapValuationAllowancesAndReservesTypeAxis_hznpAccruedCommercialRebatesAndWholesalerFeesMember_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Accrued Trade Discounts and Rebates - Schedule of Accrued Trade Discounts and Rebates (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "shortName": "Accrued Trade Discounts and Rebates - Schedule of Accrued Trade Discounts and Rebates (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapValuationAllowancesAndReservesTypeAxis_hznpAccruedCommercialRebatesAndWholesalerFeesMember_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "hznp:ScheduleOfCustomerRelatedAccrualsAndAllowancesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapValuationAllowancesAndReservesTypeAxis_hznpWholesalerFeesAndCommercialRebatesMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Accrued Trade Discounts and Rebates - Schedule of Customer-Related Accruals and Allowances (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "shortName": "Accrued Trade Discounts and Rebates - Schedule of Customer-Related Accruals and Allowances (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "hznp:ScheduleOfCustomerRelatedAccrualsAndAllowancesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapValuationAllowancesAndReservesTypeAxis_hznpWholesalerFeesAndCommercialRebatesMember_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "U_hznpSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Segment and Other Information - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "shortName": "Segment and Other Information - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_srtRangeAxis_srtMinimumMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapRevenueFromContractWithCustomerMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20200331", "decimals": "2", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Segment and Other Information - Summary of Net Sales by Medicine for Reportable Segments (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail", "shortName": "Segment and Other Information - Summary of Net Sales by Medicine for Reportable Segments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_srtProductOrServiceAxis_hznpRAVICTIMember_20200101_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Segment and Other Information - Summary of Reconciliations of Segment Operating Income (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail", "shortName": "Segment and Other Information - Summary of Reconciliations of Segment Operating Income (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20190101_20190331", "decimals": "-3", "lang": null, "name": "hznp:InventoryStepUpExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "hznp:RevenueFromContractWithCustomerExcludingAssessedTaxGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Segment and Other Information - Schedule of Gross Sales to Customers Included in Reportable Segments and All Other Customers as a Group (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "shortName": "Segment and Other Information - Schedule of Gross Sales to Customers Included in Reportable Segments and All Other Customers as a Group (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "hznp:RevenueFromContractWithCustomerExcludingAssessedTaxGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Segment and Other Information - Summary of Net Sales Attributed to Geographic Sources (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "shortName": "Segment and Other Information - Summary of Net Sales Attributed to Geographic Sources (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_srtStatementGeographicalAxis_countryUS_20200101_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Fair Value Measurements - Assets and Liabilities at Fair Value on Recurring Basis (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail", "shortName": "Fair Value Measurements - Assets and Liabilities at Fair Value on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Debt Agreements - Outstanding Debt Balances (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "shortName": "Debt Agreements - Outstanding Debt Balances (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R67": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Debt Agreements - Outstanding Debt Balances (Parenthetical) (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesParentheticalDetail", "shortName": "Debt Agreements - Outstanding Debt Balances (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Debt Agreements - Term Loan Facility and Revolving Credit Facility - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "shortName": "Debt Agreements - Term Loan Facility and Revolving Credit Facility - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LineOfCreditFacilityInterestRateDescription", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapCreditFacilityAxis_hznpTwoThousandNineteenTermLoanFacilityMember_20191218", "decimals": "INF", "lang": null, "name": "hznp:DebtInstrumentLIBORFloorRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SeniorLongTermNotes", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Debt Agreements - 2027 Senior Notes - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "shortName": "Debt Agreements - 2027 Senior Notes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapCreditFacilityAxis_hznpSeniorSecuredTermLoansMember_20190716", "decimals": "-5", "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100060 - Disclosure - Basis of Presentation and Business Overview", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverview", "shortName": "Basis of Presentation and Business Overview", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SeniorLongTermNotes", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Debt Agreements - Exchangeable Senior Notes - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "shortName": "Debt Agreements - Exchangeable Senior Notes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapDebtInstrumentAxis_hznpExchangeableSeniorNotesMember_20200101_20200331", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_srtStatementGeographicalAxis_hznpDublinOfficeMember_20200331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unitRef": "U_utrsqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Lease Obligations - Schedule of Office Space Lease Agreements in Place for Real Properties (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "shortName": "Lease Obligations - Schedule of Office Space Lease Agreements in Place for Real Properties (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_srtStatementGeographicalAxis_hznpDublinOfficeMember_20200101_20200331", "decimals": null, "lang": "en-US", "name": "us-gaap:LeaseExpirationDate1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Lease Obligations - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail", "shortName": "Lease Obligations - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "hznp:LesseeOperatingLeaseLiabilityPaymentsReceivableRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Lease Obligations - Schedule of Operating Lease Liabilities Recorded on the Balance Sheet (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail", "shortName": "Lease Obligations - Schedule of Operating Lease Liabilities Recorded on the Balance Sheet (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200331", "decimals": "-3", "first": true, "lang": null, "name": "hznp:LesseeOperatingLeaseLiabilityPaymentsReceivableRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100750 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapBusinessAcquisitionAxis_hznpRiverVisionDevelopmentCorpMember_us-gaapContingentConsiderationByTypeAxis_hznpFDAApprovalMember_20200331", "decimals": "INF", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapBusinessAcquisitionAxis_hznpRiverVisionDevelopmentCorpMember_20200331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100760 - Disclosure - Commitments and Contingencies - Summary of Remaining Aggregate Potential Milestone Payments Payable Based on Achievement of Net Sales Thresholds (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail", "shortName": "Commitments and Contingencies - Summary of Remaining Aggregate Potential Milestone Payments Payable Based on Achievement of Net Sales Thresholds (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "hznp:SummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_srtProductOrServiceAxis_hznpTeprotumumabMember_srtStatementScenarioAxis_hznpScenarioOneMember_us-gaapBusinessAcquisitionAxis_hznpRiverVisionDevelopmentCorpMember_us-gaapContingentConsiderationByTypeAxis_hznpNetSalesThresholdsMember_20200331", "decimals": "-6", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20150917_20150917", "decimals": "INF", "first": true, "lang": null, "name": "hznp:NumberOfLawsuits", "reportCount": 1, "unique": true, "unitRef": "U_hznpPatent", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100770 - Disclosure - Legal Proceedings - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail", "shortName": "Legal Proceedings - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20150917_20150917", "decimals": "INF", "first": true, "lang": null, "name": "hznp:NumberOfLawsuits", "reportCount": 1, "unique": true, "unitRef": "U_hznpPatent", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100780 - Disclosure - Share-Based and Long-Term Incentive Plans - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100790 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Stock Option Activity (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100800 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Restricted Stock Unit Activity (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Restricted Stock Unit Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100810 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Performance Stock Unit Awards Activity (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Performance Stock Unit Awards Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190101_20191231", "decimals": "3", "first": true, "lang": "en-US", "name": "hznp:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardPercentageOfNetSalesPerformanceCriteriaMet", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100820 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Performance Stock Unit Awards Activity - (Parenthetical) (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Performance Stock Unit Awards Activity - (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R82": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20200331", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100830 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Significant Valuation Assumptions Related to 2020 PSUs (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2020PsusDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Significant Valuation Assumptions Related to 2020 PSUs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20200331", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100840 - Disclosure - Share-Based and Long-Term Incentive Plans - Summary of Stock-Based Compensation Expense (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail", "shortName": "Share-Based and Long-Term Incentive Plans - Summary of Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100850 - Disclosure - Income Taxes - Benefit for Income Taxes (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxesBenefitForIncomeTaxesDetail", "shortName": "Income Taxes - Benefit for Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R85": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100860 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R86": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100870 - Disclosure - Subsequent Events - Additional Information (Detail)", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "shortName": "Subsequent Events - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_srtStatementScenarioAxis_srtScenarioForecastMember_20200401_20200630", "decimals": "-5", "lang": null, "name": "hznp:AntiHybridRulesOneTimeTaxProvisionAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Net Loss per Share", "role": "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "hznp-10q_20200331.htm", "contextRef": "C_0001492426_20200101_20200331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 147, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "verboseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r388" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r389" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "verboseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "verboseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "verboseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "hznp_AGCBiologicsASMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AGC Biologics A/S.", "label": "A G C Biologics A S [Member]", "terseLabel": "AGC Biologics A/S [Member]" } } }, "localname": "AGCBiologicsASMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_AccrualForRebatesAndTradeDiscounts": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrual for rebates and trade discounts.", "label": "Accrual For Rebates And Trade Discounts", "terseLabel": "Accrued trade discounts and rebates" } } }, "localname": "AccrualForRebatesAndTradeDiscounts", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "hznp_AccruedCoPayAndOtherPatientAssistanceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued Co-pay And Other Patient Assistance.", "label": "Accrued Co Pay And Other Patient Assistance [Member]", "terseLabel": "Accrued Co-Pay and Other Patient Assistance [Member]" } } }, "localname": "AccruedCoPayAndOtherPatientAssistanceMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail" ], "xbrltype": "domainItemType" }, "hznp_AccruedCommercialRebatesAndWholesalerFeesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued commercial rebates and wholesaler fees.", "label": "Accrued Commercial Rebates And Wholesaler Fees [Member]", "terseLabel": "Accrued Commercial Rebates and Wholesaler Fees [Member]" } } }, "localname": "AccruedCommercialRebatesAndWholesalerFeesMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail" ], "xbrltype": "domainItemType" }, "hznp_AccruedExpenseAllowancesForReturns": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued expense allowances for returns.", "label": "Accrued Expense Allowances For Returns", "terseLabel": "Allowances for returns" } } }, "localname": "AccruedExpenseAllowancesForReturns", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AccruedGovernmentRebatesAndChargeBacksMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued Government Rebates And Charge Backs.", "label": "Accrued Government Rebates And Charge Backs [Member]", "terseLabel": "Accrued Government Rebates and Chargebacks [Member]" } } }, "localname": "AccruedGovernmentRebatesAndChargeBacksMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail" ], "xbrltype": "domainItemType" }, "hznp_AccruedTradeDiscountsAndRebatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accrued trade discounts and rebates.", "label": "Accrued Trade Discounts And Rebates [Member]", "terseLabel": "Accrued Trade Discounts and Rebates [Member]" } } }, "localname": "AccruedTradeDiscountsAndRebatesMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "domainItemType" }, "hznp_AcquisitionsDivestituresAndOtherArrangementsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisitions, divestitures and other arrangements.", "label": "Acquisitions Divestitures And Other Arrangements [Text Block]", "terseLabel": "Acquisitions, Divestitures and Other Arrangements" } } }, "localname": "AcquisitionsDivestituresAndOtherArrangementsTextBlock", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangements" ], "xbrltype": "textBlockItemType" }, "hznp_ActimmuneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ACTIMMUNE.", "label": "Actimmune [Member]", "terseLabel": "ACTIMMUNE [Member]", "verboseLabel": "ACTIMMUNE Developed Technology [Member]" } } }, "localname": "ActimmuneMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_AdditionalCostsCommittedToBeIncurredForHarmonizationOfDrugSubstanceManufacturingProcess": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additional costs committed to be incurred for harmonization of drug substance manufacturing process.", "label": "Additional Costs Committed To Be Incurred For Harmonization Of Drug Substance Manufacturing Process", "terseLabel": "Additional costs committed to be incurred for harmonization of drug substance manufacturing process" } } }, "localname": "AdditionalCostsCommittedToBeIncurredForHarmonizationOfDrugSubstanceManufacturingProcess", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_AgreementExpiryDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreement expiry date.", "label": "Agreement Expiry Date", "terseLabel": "Supply agreement expiry date" } } }, "localname": "AgreementExpiryDate", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "hznp_AmortizationAndStepUpAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amortization and step-up.", "label": "Amortization And Step Up [Abstract]", "terseLabel": "Amortization and step-up:" } } }, "localname": "AmortizationAndStepUpAbstract", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "stringItemType" }, "hznp_AntiHybridRulesOneTimeTaxProvisionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Anti-hybrid rules, one-time tax provision amount.", "label": "Anti Hybrid Rules One Time Tax Provision Amount", "terseLabel": "Anti-hybrid rules, one-time tax provision amount" } } }, "localname": "AntiHybridRulesOneTimeTaxProvisionAmount", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BUPHENYLMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BUPHENYL.", "label": "B U P H E N Y L [Member]", "terseLabel": "BUPHENYL [Member]" } } }, "localname": "BUPHENYLMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_BasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of presentation.", "label": "Basis Of Presentation [Line Items]", "terseLabel": "Basis Of Presentation [Line Items]" } } }, "localname": "BasisOfPresentationLineItems", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_BasisOfPresentationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of presentation.", "label": "Basis Of Presentation [Table]", "terseLabel": "Basis Of Presentation [Table]" } } }, "localname": "BasisOfPresentationTable", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_BioTechnologyGeneralIsraelLtdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bio-Technology General (Israel) Ltd.", "label": "Bio Technology General Israel Ltd [Member]", "terseLabel": "Bio-Technology General (Israel) Ltd [Member]" } } }, "localname": "BioTechnologyGeneralIsraelLtdMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_BoehringerIngelheimMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boehringer Ingelheim.", "label": "Boehringer Ingelheim [Member]", "terseLabel": "Boehringer Ingelheim [Member]" } } }, "localname": "BoehringerIngelheimMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_BusinessCombinationProgressPaymentsPaidUnderCollaborationAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business combination progress payments paid under collaboration agreement.", "label": "Business Combination Progress Payments Paid Under Collaboration Agreement", "verboseLabel": "Business combination progress payments paid under collaboration agreement." } } }, "localname": "BusinessCombinationProgressPaymentsPaidUnderCollaborationAgreement", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_BusinessCombinationUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination upfront payment.", "label": "Business Combination Upfront Payment", "terseLabel": "Upfront cash payment" } } }, "localname": "BusinessCombinationUpfrontPayment", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_CambrexProfarmacoMilanoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cambrex Profarmaco Milano.", "label": "Cambrex Profarmaco Milano [Member]", "terseLabel": "Cambrex [Member]" } } }, "localname": "CambrexProfarmacoMilanoMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_CashBonusAwardDeterminationPercentageOnAchievementOfPatientEnrollmentLevelsMaximumTargetLevel": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash bonus award determination percentage on achievement of patient enrollment levels maximum target level", "label": "Cash Bonus Award Determination Percentage On Achievement Of Patient Enrollment Levels Maximum Target Level", "terseLabel": "Cash bonus award maximum target level" } } }, "localname": "CashBonusAwardDeterminationPercentageOnAchievementOfPatientEnrollmentLevelsMaximumTargetLevel", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash paid for amounts included in measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hznp_CatalentIndianaLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Catalent Indiana LLC.", "label": "Catalent Indiana L L C [Member]", "terseLabel": "Catalent [Member]" } } }, "localname": "CatalentIndianaLLCMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ChangeInEscrowDepositForPropertyPurchase": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Change in escrow deposit for property purchase.", "label": "Change In Escrow Deposit For Property Purchase", "negatedLabel": "Change in escrow deposit for property purchase" } } }, "localname": "ChangeInEscrowDepositForPropertyPurchase", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hznp_ChicagoOfficeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Chicago office.", "label": "Chicago Office [Member]", "terseLabel": "Chicago Office [Member]" } } }, "localname": "ChicagoOfficeMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_CoPayAndOtherPatientAssistanceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Co-pay and other patient assistance.", "label": "Co Pay And Other Patient Assistance [Member]", "terseLabel": "Co-Pay and Other Patient Assistance [Member]" } } }, "localname": "CoPayAndOtherPatientAssistanceMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "domainItemType" }, "hznp_ConversionConditionOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Conversion condition one.", "label": "Conversion Condition One [Member]", "terseLabel": "Conversion Condition One [Member]" } } }, "localname": "ConversionConditionOneMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ConversionConditionTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Conversion condition two.", "label": "Conversion Condition Two [Member]", "terseLabel": "Conversion Condition Two [Member]" } } }, "localname": "ConversionConditionTwoMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_CosettePharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cosette Pharmaceuticals, Inc.", "label": "Cosette Pharmaceuticals Inc [Member]", "terseLabel": "Cosette Pharmaceuticals, Inc [Member]" } } }, "localname": "CosettePharmaceuticalsIncMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit agreement.", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_CurzionPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Curzion Pharmaceuticals, Inc.", "label": "Curzion Pharmaceuticals Inc [Member]", "terseLabel": "Curzion Pharmaceuticals, Inc [Member]" } } }, "localname": "CurzionPharmaceuticalsIncMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_CustomerAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer A.", "label": "Customer A [Member]", "terseLabel": "Customer A [Member]" } } }, "localname": "CustomerAMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_CustomerBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer B.", "label": "Customer B [Member]", "terseLabel": "Customer B [Member]" } } }, "localname": "CustomerBMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_CustomerCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer C.", "label": "Customer C [Member]", "terseLabel": "Customer C [Member]" } } }, "localname": "CustomerCMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_CustomerDMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer D.", "label": "Customer D [Member]", "terseLabel": "Customer D [Member]" } } }, "localname": "CustomerDMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_DUEXISProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DUEXIS Product.", "label": "D U E X I S Product [Member]", "terseLabel": "DUEXIS [Member]" } } }, "localname": "DUEXISProductMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt instrument convertible carrying amount of liability component.", "label": "Debt Instrument Convertible Carrying Amount Of Liability Component", "terseLabel": "Carrying amount of liability component" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfLiabilityComponent", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DebtInstrumentConvertibleThresholdMaximumPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument, convertible, threshold maximum percentage of stock price trigger.", "label": "Debt Instrument Convertible Threshold Maximum Percentage Of Stock Price Trigger", "terseLabel": "Debt instrument convertible maximum percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdMaximumPercentageOfStockPriceTrigger", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DebtInstrumentCovenantComplianceMinimumPercentageOfRevolvingCreditCommitments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument, covenant compliance, minimum percentage of revolving credit commitments.", "label": "Debt Instrument Covenant Compliance Minimum Percentage Of Revolving Credit Commitments", "terseLabel": "Minimum percentage of total commitments" } } }, "localname": "DebtInstrumentCovenantComplianceMinimumPercentageOfRevolvingCreditCommitments", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DebtInstrumentLIBORFloorRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument LIBOR floor rate.", "label": "Debt Instrument L I B O R Floor Rate", "terseLabel": "LIBOR floor rate" } } }, "localname": "DebtInstrumentLIBORFloorRate", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DebtInstrumentLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument leverage ratio.", "label": "Debt Instrument Leverage Ratio", "terseLabel": "Debt instrument leverage ratio" } } }, "localname": "DebtInstrumentLeverageRatio", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DebtInstrumentRedemptionInWholeButNotInPartMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument redemption in whole but not in part.", "label": "Debt Instrument Redemption In Whole But Not In Part [Member]", "terseLabel": "After August 1, 2022, in Whole But Not in Part [Member]" } } }, "localname": "DebtInstrumentRedemptionInWholeButNotInPartMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_DebtInstrumentRedemptionPricePercentageOnChangeOfControl": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument redemption price percentage on change of control.", "label": "Debt Instrument Redemption Price Percentage On Change Of Control", "terseLabel": "Redemption price percentage of principal amount of debt instrument on change of control" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOnChangeOfControl", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DebtInstrumentRedemptionSomeOrAllMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument redemption some or all.", "label": "Debt Instrument Redemption Some Or All [Member]", "terseLabel": "Prior to August 1, 2022, Some or All of Aggregate Principal Amount [Member]" } } }, "localname": "DebtInstrumentRedemptionSomeOrAllMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_DebtInstrumentRedemptionUpToFortyPercentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt instrument redemption up to forty percent.", "label": "Debt Instrument Redemption Up To Forty Percent [Member]", "terseLabel": "Prior to August 1, 2022 [Member]" } } }, "localname": "DebtInstrumentRedemptionUpToFortyPercentMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_DecreaseInPercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Decrease in percentage on excess cash flow for mandatory prepayments of debt.", "label": "Decrease In Percentage On Excess Cash Flow For Mandatory Prepayments Of Debt", "terseLabel": "Proceeds from debt issuances, reduction percentage on excess cash flow" } } }, "localname": "DecreaseInPercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_DeerfieldIllinoisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deerfield, Illinois.", "label": "Deerfield Illinois [Member]", "terseLabel": "Deerfield, Illinois [Member]" } } }, "localname": "DeerfieldIllinoisMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_DeferredTaxChargeOnIntraCompanyProfit": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10010.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred tax charge on intra-company profit.", "label": "Deferred Tax Charge On Intra Company Profit", "terseLabel": "Deferred charge for taxes on intra-company profit" } } }, "localname": "DeferredTaxChargeOnIntraCompanyProfit", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DisposalGroupNotDiscontinuedOperationContingentConsiderationPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal group not discontinued operation contingent consideration payment.", "label": "Disposal Group Not Discontinued Operation Contingent Consideration Payment", "terseLabel": "Potential additional contingent consideration payment" } } }, "localname": "DisposalGroupNotDiscontinuedOperationContingentConsiderationPayment", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DisposalGroupNotDiscontinuedOperationDevelopedTechnology": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail": { "order": 10020.0, "parentTag": "us-gaap_GainLossOnDispositionOfAssets1", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal group not discontinued operation developed technology.", "label": "Disposal Group Not Discontinued Operation Developed Technology", "negatedLabel": "Developed technology" } } }, "localname": "DisposalGroupNotDiscontinuedOperationDevelopedTechnology", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DisposalGroupNotDiscontinuedOperationInventory": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail": { "order": 10030.0, "parentTag": "us-gaap_GainLossOnDispositionOfAssets1", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disposal group not discontinued operation inventory.", "label": "Disposal Group Not Discontinued Operation Inventory", "negatedLabel": "Inventory" } } }, "localname": "DisposalGroupNotDiscontinuedOperationInventory", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DisposalGroupNotDiscontinuedOperationNetAssetsSoldAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disposal group not discontinued operation net assets sold.", "label": "Disposal Group Not Discontinued Operation Net Assets Sold [Abstract]", "terseLabel": "Less net assets sold:" } } }, "localname": "DisposalGroupNotDiscontinuedOperationNetAssetsSoldAbstract", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail" ], "xbrltype": "stringItemType" }, "hznp_DisposalGroupNotDiscontinuedOperationReleaseOfContingentConsiderationLiability": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail": { "order": 10040.0, "parentTag": "us-gaap_GainLossOnDispositionOfAssets1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Disposal group not discontinued operation release of contingent consideration liability.", "label": "Disposal Group Not Discontinued Operation Release Of Contingent Consideration Liability", "terseLabel": "Release of contingent consideration liability" } } }, "localname": "DisposalGroupNotDiscontinuedOperationReleaseOfContingentConsiderationLiability", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DrugSubstanceHarmonizationCosts": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10080.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Drug substance harmonization costs.", "label": "Drug Substance Harmonization Costs", "negatedLabel": "Drug substance harmonization costs" } } }, "localname": "DrugSubstanceHarmonizationCosts", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "hznp_DublinOfficeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dublin office.", "label": "Dublin Office [Member]", "terseLabel": "Dublin Office [Member]" } } }, "localname": "DublinOfficeMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "hznp_EmployeeServiceShareBasedCompensationTaxBenefitDetrimentFromCompensationExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Employee service share based compensation tax benefit (detriment) from compensation expense.", "label": "Employee Service Share Based Compensation Tax Benefit Detriment From Compensation Expense", "terseLabel": "Tax benefit (detriment) recognized from stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitDetrimentFromCompensationExpense", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_ExchangeableSeniorNotesDueTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exchangeable senior notes due twenty twenty two.", "label": "Exchangeable Senior Notes Due Twenty Twenty Two [Member]", "verboseLabel": "Exchangeable Senior Notes due 2022 [Member]" } } }, "localname": "ExchangeableSeniorNotesDueTwentyTwentyTwoMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesParentheticalDetail" ], "xbrltype": "domainItemType" }, "hznp_ExchangeableSeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exchangeable senior notes.", "label": "Exchangeable Senior Notes [Member]", "terseLabel": "Exchangeable Senior Notes [Member]" } } }, "localname": "ExchangeableSeniorNotesMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ExpectedAgreementExpirationDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Expected agreement expiration date.", "label": "Expected Agreement Expiration Date", "terseLabel": "Expected early termination period of agreement due to uncertain event" } } }, "localname": "ExpectedAgreementExpirationDate", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "hznp_FDAApprovalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "FDA approval.", "label": "F D A Approval [Member]", "terseLabel": "FDA Approval [Member]" } } }, "localname": "FDAApprovalMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_FirstLienLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First lien leverage ratio.", "label": "First Lien Leverage Ratio", "terseLabel": "First lien leverage ratio" } } }, "localname": "FirstLienLeverageRatio", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_ForeignExchangeGainLossAndOtherAdjustments": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Foreign exchange gain loss and other adjustments.", "label": "Foreign Exchange Gain Loss And Other Adjustments", "negatedLabel": "Foreign exchange and other adjustments" } } }, "localname": "ForeignExchangeGainLossAndOtherAdjustments", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hznp_GainsLossesOnExtinguishmentOfDebtExcludingCashAndNonCash": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10120.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gains losses on extinguishment of debt excluding cash and non-cash.", "label": "Gains Losses On Extinguishment Of Debt Excluding Cash And Non Cash", "terseLabel": "Loss on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtExcludingCashAndNonCash", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "hznp_GainsLossesOnExtinguishmentOfDebtIncludingCashAndNonCash": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10090.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gains losses on extinguishment of debt including cash and non-cash.", "label": "Gains Losses On Extinguishment Of Debt Including Cash And Non Cash", "terseLabel": "Loss on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebtIncludingCashAndNonCash", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "hznp_GovernmentRebatesAndChargeBacksMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Government rebates and charge backs.", "label": "Government Rebates And Charge Backs [Member]", "terseLabel": "Government Rebates and Chargebacks [Member]" } } }, "localname": "GovernmentRebatesAndChargeBacksMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "domainItemType" }, "hznp_HemoShearTherapeuticsLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "HemoShear Therapeutics, LLC.", "label": "Hemo Shear Therapeutics Limited Liability Company [Member]", "terseLabel": "HemoShear [Member]" } } }, "localname": "HemoShearTherapeuticsLimitedLiabilityCompanyMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_HorizonPharmaSubsidiariesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Horizon Pharma subsidiaries.", "label": "Horizon Pharma Subsidiaries [Member]", "terseLabel": "Horizon Pharma Subsidiaries [Member]" } } }, "localname": "HorizonPharmaSubsidiariesMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_HorizonPharmaUSAIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Horizon Pharma USA Inc.", "label": "Horizon Pharma U S A Inc [Member]", "terseLabel": "Horizon Pharma USA Inc [Member]" } } }, "localname": "HorizonPharmaUSAIncMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_HyperionTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hyperion therapeutics Inc.", "label": "Hyperion Therapeutics Inc [Member]", "terseLabel": "Hyperion Therapeutics, Inc. [Member]" } } }, "localname": "HyperionTherapeuticsIncMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_IncreaseDecreaseInAccruedTradeDiscountsAndRebates": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase decrease in accrued trade discounts and rebates.", "label": "Increase Decrease In Accrued Trade Discounts And Rebates", "terseLabel": "Accrued trade discounts and rebates" } } }, "localname": "IncreaseDecreaseInAccruedTradeDiscountsAndRebates", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "hznp_IncreaseDecreaseInFeesRelatedToRefinancingActivities": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10100.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase decrease in fees related to refinancing activities.", "label": "Increase Decrease In Fees Related To Refinancing Activities", "terseLabel": "Fees related to refinancing activities" } } }, "localname": "IncreaseDecreaseInFeesRelatedToRefinancingActivities", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "hznp_InflammationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inflammation member.", "label": "Inflammation [Member]", "terseLabel": "Inflammation [Member]" } } }, "localname": "InflammationMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "domainItemType" }, "hznp_InventoryStepUpExpense": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10040.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventory step-up expense.", "label": "Inventory Step Up Expense", "negatedLabel": "Inventory step-up expense" } } }, "localname": "InventoryStepUpExpense", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "hznp_InvoicedWholesalerFeesAndCommercialRebatesCoPayAndOtherPatientAssistanceCostsAndGovernmentRebatesAndChargebacksInAccountsPayableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Invoiced wholesaler fees and commercial rebates, co-pay and other patient assistance costs, and government rebates and chargebacks in accounts payable.", "label": "Invoiced Wholesaler Fees And Commercial Rebates Co Pay And Other Patient Assistance Costs And Government Rebates And Chargebacks In Accounts Payable [Member]", "terseLabel": "Invoiced Commercial Rebates and Wholesaler Fees, Co pay and Other Patient Assistance Costs, and Government Rebates and Chargebacks in Accounts Payable [Member]" } } }, "localname": "InvoicedWholesalerFeesAndCommercialRebatesCoPayAndOtherPatientAssistanceCostsAndGovernmentRebatesAndChargebacksInAccountsPayableMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail" ], "xbrltype": "domainItemType" }, "hznp_KRYSTEXXAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "KRYSTEXXA.", "label": "K R Y S T E X X A [Member]", "terseLabel": "KRYSTEXXA Developed Technology [Member]", "verboseLabel": "KRYSTEXXA [Member]" } } }, "localname": "KRYSTEXXAMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_LakeForestOfficeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lake forest office.", "label": "Lake Forest Office [Member]", "terseLabel": "Lake Forest Office [Member]" } } }, "localname": "LakeForestOfficeMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_LesseeOperatingLeaseLiabilityPaymentsReceivableRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee operating lease liability payments receivable remainder of fiscal year.", "label": "Lessee Operating Lease Liability Payments Receivable Remainder Of Fiscal Year", "terseLabel": "Operating Lease liabilities, 2020 (April to December)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsReceivableRemainderOfFiscalYear", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "hznp_LetterOfCreditSubFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Letter of credit sub-facility.", "label": "Letter Of Credit Sub Facility [Member]", "terseLabel": "Letter of Credit Sub-facility [Member]" } } }, "localname": "LetterOfCreditSubFacilityMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Line of credit facility additional borrowing capacity.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of credit facility additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_LineOfCreditFacilityExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line of credit facility, expiration month and year.", "label": "Line Of Credit Facility Expiration Month And Year", "terseLabel": "Line of credit facility termination period" } } }, "localname": "LineOfCreditFacilityExpirationMonthAndYear", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "hznp_LongTermPurchaseCommitmentAgreementExpireDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long term purchase commitment agreement expire date.", "label": "Long Term Purchase Commitment Agreement Expire Date", "terseLabel": "Term of agreement expiration month and year" } } }, "localname": "LongTermPurchaseCommitmentAgreementExpireDate", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "hznp_LongTermPurchaseCommitmentAgreementRenewalPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long term purchase commitment agreement renewal period.", "label": "Long Term Purchase Commitment Agreement Renewal Period", "terseLabel": "Term of agreement automatically renewal period" } } }, "localname": "LongTermPurchaseCommitmentAgreementRenewalPeriod", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "hznp_LongTermPurchaseCommitmentNoticePeriodForTerminationOfAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term purchase commitment notice period for termination of agreement.", "label": "Long Term Purchase Commitment Notice Period For Termination Of Agreement", "terseLabel": "Written notice period for termination of agreement" } } }, "localname": "LongTermPurchaseCommitmentNoticePeriodForTerminationOfAgreement", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "hznp_LundbeckfondMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lundbeckfond.", "label": "Lundbeckfond [Member]", "terseLabel": "Lundbeckfond [Member]" } } }, "localname": "LundbeckfondMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_LundquistInstituteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lundquist institute.", "label": "Lundquist Institute [Member]", "terseLabel": "Lundquist Institute [Member]" } } }, "localname": "LundquistInstituteMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_MIGERGOTMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MIGERGOT.", "label": "M I G E R G O T [Member]", "terseLabel": "MIGERGOT [Member]" } } }, "localname": "MIGERGOTMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_MIGERGOTTransactionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MIGERGOT transaction member", "label": "M I G E R G O T Transaction [Member]", "terseLabel": "MIGERGOT Transaction [Member]" } } }, "localname": "MIGERGOTTransactionMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_MandatoryPrepaymentProvisionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mandatory prepayment provisions.", "label": "Mandatory Prepayment Provisions [Member]", "terseLabel": "Mandatory Prepayment Provisions [Member]" } } }, "localname": "MandatoryPrepaymentProvisionsMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_MannheimOfficeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mannheim office.", "label": "Mannheim Office [Member]", "terseLabel": "Mannheim Office [Member]" } } }, "localname": "MannheimOfficeMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_MayTwoThousandNineteenRefinancingLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "May two thousand nineteen refinancing loans member.", "label": "May Two Thousand Nineteen Refinancing Loans [Member]", "terseLabel": "May 2019 Refinancing Loans [Member]" } } }, "localname": "MayTwoThousandNineteenRefinancingLoansMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_MembersOfExecutiveCommitteeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Members of executive committee.", "label": "Members Of Executive Committee [Member]", "terseLabel": "Members of Executive Committee [Member]" } } }, "localname": "MembersOfExecutiveCommitteeMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_MilestonePaymentUnderLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Milestone payment under license agreement.", "label": "Milestone Payment Under License Agreement", "terseLabel": "Milestone incurred" } } }, "localname": "MilestonePaymentUnderLicenseAgreement", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_NetSalesThresholdsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net sales thresholds.", "label": "Net Sales Thresholds [Member]", "terseLabel": "Net Sales Thresholds [Member]" } } }, "localname": "NetSalesThresholdsMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "domainItemType" }, "hznp_NewIncrementalRevolvingCommitmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "New Incremental Revolving Commitments.", "label": "New Incremental Revolving Commitments [Member]", "terseLabel": "New Incremental Revolving Commitments [Member]" } } }, "localname": "NewIncrementalRevolvingCommitmentsMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_NovatoOfficeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Novato office.", "label": "Novato Office [Member]", "terseLabel": "Novato Office [Member]" } } }, "localname": "NovatoOfficeMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_NumberOfAdditionalLawsuits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional lawsuits.", "label": "Number Of Additional Lawsuits", "terseLabel": "Number of additional lawsuits" } } }, "localname": "NumberOfAdditionalLawsuits", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "hznp_NumberOfBuilding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of building.", "label": "Number Of Building", "terseLabel": "Number of building purchased" } } }, "localname": "NumberOfBuilding", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "hznp_NumberOfLawsuits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of lawsuits.", "label": "Number Of Lawsuits", "terseLabel": "Number of lawsuits" } } }, "localname": "NumberOfLawsuits", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "hznp_NuvoPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nuvo Pharmaceuticals Inc.", "label": "Nuvo Pharmaceuticals Inc [Member]", "terseLabel": "Nuvo Pharmaceuticals Inc. [Member]" } } }, "localname": "NuvoPharmaceuticalsIncMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_OneTimePaymentInExchangeOfMilestoneAndRoyaltyPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "One time payment in exchange of milestone and royalty payments.", "label": "One Time Payment In Exchange Of Milestone And Royalty Payments", "terseLabel": "One-time payment in exchange of milestone and royalty payments" } } }, "localname": "OneTimePaymentInExchangeOfMilestoneAndRoyaltyPayments", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_OrphanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Orphan.", "label": "Orphan [Member]", "terseLabel": "Orphan [Member]" } } }, "localname": "OrphanMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "domainItemType" }, "hznp_OrphanSegmentNetSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Orphan Segment Net Sales.", "label": "Orphan Segment Net Sales [Member]", "terseLabel": "Orphan Segment Net Sales [Member]" } } }, "localname": "OrphanSegmentNetSalesMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_OtherCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other customers.", "label": "Other Customers [Member]", "terseLabel": "Other Customers [Member]" } } }, "localname": "OtherCustomersMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "hznp_OtherOfficeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other office.", "label": "Other Office [Member]", "terseLabel": "Other Office" } } }, "localname": "OtherOfficeMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_OtherPrepaidExpensesAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10050.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other prepaid expenses and other current assets.", "label": "Other Prepaid Expenses And Other Current Assets", "terseLabel": "Other prepaid expenses and other current assets" } } }, "localname": "OtherPrepaidExpensesAndOtherCurrentAssets", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_OutOfPeriodAdjustmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Out of period adjustments.", "label": "Out Of Period Adjustments [Member]", "terseLabel": "Out of Period Adjustments [Member]" } } }, "localname": "OutOfPeriodAdjustmentsMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_PENNSAIDTwoPercentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "PENNSAID two percent.", "label": "P E N N S A I D Two Percent [Member]", "terseLabel": "PENNSAID 2% [Member]" } } }, "localname": "PENNSAIDTwoPercentMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_PROCYSBIAPIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "PROCYSBI API.", "label": "P R O C Y S B I A P I [Member]", "terseLabel": "PROCYSBI API [Member]" } } }, "localname": "PROCYSBIAPIMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_PROCYSBIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "PROCYSBI.", "label": "P R O C Y S B I [Member]", "terseLabel": "PROCYSBI [Member]", "verboseLabel": "PROCYSBI Developed Technology [Member]" } } }, "localname": "PROCYSBIMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_PatheonUSAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Patheon USA.", "label": "Patheon U S A [Member]", "terseLabel": "Patheon Pharmaceuticals Inc. [Member]" } } }, "localname": "PatheonUSAMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_PercentOfPremiumOnRepaymentOfDebt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of premium on repayment of debt.", "label": "Percent Of Premium On Repayment Of Debt", "terseLabel": "Premium on repayment of debt" } } }, "localname": "PercentOfPremiumOnRepaymentOfDebt", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOfNetSalesInEarnOutPayment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of net sales in earn-out payment.", "label": "Percentage Of Net Sales In Earn Out Payment", "terseLabel": "Percentage of net sales in earn-out payment" } } }, "localname": "PercentageOfNetSalesInEarnOutPayment", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOfRemainingNetObligationsPayments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of remaining net obligations payments.", "label": "Percentage Of Remaining Net Obligations Payments", "terseLabel": "Percentage of remaining net obligations payments" } } }, "localname": "PercentageOfRemainingNetObligationsPayments", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOfRightToReceivePayments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of right to receive payments.", "label": "Percentage Of Right To Receive Payments", "terseLabel": "Percentage of right to receive payments" } } }, "localname": "PercentageOfRightToReceivePayments", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage on excess cash flow for mandatory prepayments of debt.", "label": "Percentage On Excess Cash Flow For Mandatory Prepayments Of Debt", "terseLabel": "Proceeds from debt issuances, percentage on excess cash flow" } } }, "localname": "PercentageOnExcessCashFlowForMandatoryPrepaymentsOfDebt", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PercentageOnFirstLienLeverageRatioForMandatoryPrepaymentsOfDebt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage on first lien leverage ratio for mandatory prepayments of debt.", "label": "Percentage On First Lien Leverage Ratio For Mandatory Prepayments Of Debt", "terseLabel": "Proceeds from debt issuances, percentage on first lien leverage ratio" } } }, "localname": "PercentageOnFirstLienLeverageRatioForMandatoryPrepaymentsOfDebt", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "prepaid expenses and other current assets disclosure text block.", "label": "Prepaid Expenses And Other Current Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "hznp_PrepaidIncomeTaxesAndIncomeTaxReceivable": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10020.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid income taxes and income tax receivable.", "label": "Prepaid Income Taxes And Income Tax Receivable", "terseLabel": "Prepaid income taxes and income tax receivable" } } }, "localname": "PrepaidIncomeTaxesAndIncomeTaxReceivable", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PricesReviewLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10050.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Prices review liability current.", "label": "Prices Review Liability Current", "terseLabel": "Pricing review liability" } } }, "localname": "PricesReviewLiabilityCurrent", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PropertyAndEquipmentExpectedUsefulLifeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Property And Equipment Expected Useful Life Table [Text Block]", "label": "Property And Equipment Expected Useful Life Table [Text Block]", "terseLabel": "Depreciation and Amortization Periods for Property and Equipment" } } }, "localname": "PropertyAndEquipmentExpectedUsefulLifeTableTextBlock", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "hznp_PurchaseAndOtherCommitmentsOutstandingPurchaseOrders": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Purchase and other commitments outstanding purchase orders.", "label": "Purchase And Other Commitments Outstanding Purchase Orders", "terseLabel": "Purchase and other commitments outstanding purchase orders" } } }, "localname": "PurchaseAndOtherCommitmentsOutstandingPurchaseOrders", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PurchaseCommitmentOutstandingPurchaseOrders": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Purchase commitment outstanding purchase orders.", "label": "Purchase Commitment Outstanding Purchase Orders", "terseLabel": "Purchase commitment outstanding purchase orders" } } }, "localname": "PurchaseCommitmentOutstandingPurchaseOrders", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_PurchaseObligationPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase obligation percentage.", "label": "Purchase Obligation Percentage", "terseLabel": "Purchase obligation percentage" } } }, "localname": "PurchaseObligationPercentage", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_QUINSAIRMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "QUINSAIR.", "label": "Q U I N S A I R [Member]", "terseLabel": "QUINSAIR [Member]" } } }, "localname": "QUINSAIRMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_RAVICTIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RAVICTI.", "label": "R A V I C T I [Member]", "terseLabel": "RAVICTI [Member]" } } }, "localname": "RAVICTIMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_RAYOSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RAYOS.", "label": "R A Y O S [Member]", "terseLabel": "RAYOS [Member]" } } }, "localname": "RAYOSMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_RabbiTrustAssets": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10040.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rabbi trust assets.", "label": "Rabbi Trust Assets", "terseLabel": "Rabbi trust assets" } } }, "localname": "RabbiTrustAssets", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "hznp_RavictiAndBuphenylAndRayosAndQuinsairMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RAVICTI, BUPHENYL, RAYOS and QUINSAIR.", "label": "Ravicti And Buphenyl And Rayos And Quinsair [Member]", "terseLabel": "RAVICTI, BUPHENYL, RAYOS and QUINSAIR [Member]" } } }, "localname": "RavictiAndBuphenylAndRayosAndQuinsairMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ReducedMarginBasedOnLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reduced margin based on leverage ratio.", "label": "Reduced Margin Based On Leverage Ratio", "terseLabel": "Leverage ratio less than applicable margin" } } }, "localname": "ReducedMarginBasedOnLeverageRatio", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "hznp_RefinancingLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Refinancing loans.", "label": "Refinancing Loans [Member]", "terseLabel": "Refinancing Loans [Member]" } } }, "localname": "RefinancingLoansMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_RevenueFromContractWithCustomerExcludingAssessedTaxGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue from contract with customer excluding assessed tax, gross.", "label": "Revenue From Contract With Customer Excluding Assessed Tax Gross", "terseLabel": "Gross Sales, Amount" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxGross", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "monetaryItemType" }, "hznp_RiverVisionDevelopmentCorpMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "River Vision Development Corp.", "label": "River Vision Development Corp [Member]", "terseLabel": "River Vision [Member]" } } }, "localname": "RiverVisionDevelopmentCorpMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "domainItemType" }, "hznp_RocheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Roche.", "label": "Roche [Member]", "terseLabel": "Roche [Member]" } } }, "localname": "RocheMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_SROneAndLundbeckfondMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "S.R. One and Lundbeckfond.", "label": "S R One And Lundbeckfond [Member]", "terseLabel": "S.R. One and Lundbeckfond [Member]" } } }, "localname": "SROneAndLundbeckfondMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_SROneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "S.R. One.", "label": "S R One [Member]", "terseLabel": "S.R. One [Member]" } } }, "localname": "SROneMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_SalesRevenueNetMinimumLimitForRoyaltyPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sales revenue net minimum limit for royalty payment.", "label": "Sales Revenue Net Minimum Limit For Royalty Payment", "terseLabel": "Net sales minimum limit for royal payment" } } }, "localname": "SalesRevenueNetMinimumLimitForRoyaltyPayment", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "hznp_SanofiAventisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sanofi Aventis.", "label": "Sanofi Aventis [Member]", "terseLabel": "Sanofi-Aventis U.S [Member]" } } }, "localname": "SanofiAventisMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ScenarioOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Scenario one.", "label": "Scenario One [Member]", "terseLabel": "TEPEZZA Worldwide Net Sales Threshold >$250 million [Member]" } } }, "localname": "ScenarioOneMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "domainItemType" }, "hznp_ScenarioThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Scenario three.", "label": "Scenario Three [Member]", "terseLabel": "TEPEZZA Worldwide Net Sales Threshold >$500million [Member]" } } }, "localname": "ScenarioThreeMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "domainItemType" }, "hznp_ScenarioTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Scenario two.", "label": "Scenario Two [Member]", "terseLabel": "TEPEZZA Worldwide Net Sales Threshold >$375 million [Member]" } } }, "localname": "ScenarioTwoMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "domainItemType" }, "hznp_ScheduleOfCustomerRelatedAccrualsAndAllowancesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of customer related accruals and allowances.", "label": "Schedule Of Customer Related Accruals And Allowances Table [Text Block]", "terseLabel": "Schedule of Customer-Related Accruals and Allowances" } } }, "localname": "ScheduleOfCustomerRelatedAccrualsAndAllowancesTableTextBlock", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "textBlockItemType" }, "hznp_ScheduleOfShareBasedPaymentAwardPerformanceStockUnitsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of share based payment award performance stock units valuation assumptions table text block.", "label": "Schedule Of Share Based Payment Award Performance Stock Units Valuation Assumptions Table [Text Block]", "terseLabel": "Summary of Significant Valuation Assumptions Related to 2020 PSUs" } } }, "localname": "ScheduleOfShareBasedPaymentAwardPerformanceStockUnitsValuationAssumptionsTableTextBlock", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "hznp_SeniorNotesDueTwentyTwentySevenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior notes due twenty twenty seven.", "label": "Senior Notes Due Twenty Twenty Seven [Member]", "verboseLabel": "Senior Notes due 2027 [Member]" } } }, "localname": "SeniorNotesDueTwentyTwentySevenMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesParentheticalDetail" ], "xbrltype": "domainItemType" }, "hznp_SeniorSecuredTermLoansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior secured term loans.", "label": "Senior Secured Term Loans [Member]", "terseLabel": "Senior Secured Term Loan [Member]" } } }, "localname": "SeniorSecuredTermLoansMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options forfeited in period average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Average Illiquidity Discount", "terseLabel": "Average Illiquidity discount, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodAverageIlliquidityDiscount", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options forfeited in period recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period Recorded Weighted Average Fair Value", "terseLabel": "Recorded Weighted Average Fair Value Per Unit, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodRecordedWeightedAverageFairValue", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Average Illiquidity Discount", "terseLabel": "Average Illiquidity discount, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAverageIlliquidityDiscount", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Recorded Weighted Average Fair Value", "terseLabel": "Recorded Weighted Average Fair Value Per Unit, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRecordedWeightedAverageFairValue", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Average Illiquidity Discount", "periodEndLabel": "Average Illiquidity discount, Outstanding Ending Balance", "periodStartLabel": "Average Illiquidity discount, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedAverageIlliquidityDiscount", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options nonvested recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Recorded Weighted Average Fair Value", "periodEndLabel": "Recorded Weighted Average Fair Value Per Unit, Outstanding Ending Balance", "periodStartLabel": "Recorded Weighted Average Fair Value Per Unit, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRecordedWeightedAverageFairValue", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance based adjustment in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Performance Based Adjustment In Period", "terseLabel": "Number of Units, Performance Based Adjustment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriod", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "sharesItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance based adjustment in period average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Performance Based Adjustment In Period Average Illiquidity Discount", "terseLabel": "Average Illiquidity discount, Performance Based Adjustment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodAverageIlliquidityDiscount", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance based adjustment in period recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Performance Based Adjustment In Period Recorded Weighted Average Fair Value", "terseLabel": "Recorded Weighted Average Fair Value Per Unit, Performance Based Adjustment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodRecordedWeightedAverageFairValue", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options performance based adjustment in period weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Performance Based Adjustment In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant-Date Fair Value Per Unit, Performance Based Adjustment" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformanceBasedAdjustmentInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodAverageIlliquidityDiscount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested in period average illiquidity discount.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Average Illiquidity Discount", "terseLabel": "Average Illiquidity discount, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodAverageIlliquidityDiscount", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "percentItemType" }, "hznp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRecordedWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested in period recorded weighted average fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Recorded Weighted Average Fair Value", "terseLabel": "Recorded Weighted Average Fair Value Per Unit, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodRecordedWeightedAverageFairValue", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail" ], "xbrltype": "perShareItemType" }, "hznp_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardPercentageOfNetSalesPerformanceCriteriaMet": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award award percentage of net sales performance criteria met.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Percentage Of Net Sales Performance Criteria Met", "terseLabel": "Percentage of net sales performance criteria met" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardPercentageOfNetSalesPerformanceCriteriaMet", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "percentItemType" }, "hznp_SouthSanFranciscoOfficeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "South san francisco office.", "label": "South San Francisco Office [Member]", "terseLabel": "South San Francisco Office [Member]" } } }, "localname": "SouthSanFranciscoOfficeMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "domainItemType" }, "hznp_SummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of remaining aggregate potential milestone payments payable based on achievement of net sales thresholds.", "label": "Summary Of Remaining Aggregate Potential Milestone Payments Payable Based On Achievement Of Net Sales Thresholds Table [Text Block]", "terseLabel": "Summary of Remaining Aggregate Potential Milestone Payments Payable Based on Achievement of Net Sales Thresholds" } } }, "localname": "SummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsTableTextBlock", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "hznp_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "hznp_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "hznp_TEPEZZADevelopedTechnologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "TEPEZZA developed technology.", "label": "T E P E Z Z A Developed Technology [Member]", "terseLabel": "TEPEZZA Developed Technology [Member]" } } }, "localname": "TEPEZZADevelopedTechnologyMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TEPEZZADrugProductMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "TEPEZZA drug product.", "label": "T E P E Z Z A Drug Product [Member]", "terseLabel": "TEPEZZA Drug Product [Member]" } } }, "localname": "TEPEZZADrugProductMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TEPEZZADrugSubstanceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "TEPEZZA drug member.", "label": "T E P E Z Z A Drug Substance [Member]", "terseLabel": "TEPEZZA [Member]" } } }, "localname": "TEPEZZADrugSubstanceMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TEPEZZAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "TEPEZZA.", "label": "T E P E Z Z A [Member]", "terseLabel": "TEPEZZA [Member]" } } }, "localname": "TEPEZZAMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TeprotumumabMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Teprotumumab.", "label": "Teprotumumab [Member]", "terseLabel": "Teprotumumab [Member]" } } }, "localname": "TeprotumumabMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "domainItemType" }, "hznp_TermLoanFacilityDueTwentyTwentySixMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term loan facility due twenty twenty six.", "label": "Term Loan Facility Due Twenty Twenty Six [Member]", "verboseLabel": "Term Loan Facility due 2026 [Member]" } } }, "localname": "TermLoanFacilityDueTwentyTwentySixMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesParentheticalDetail" ], "xbrltype": "domainItemType" }, "hznp_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term loan facility.", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility [Member]" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TradeshowEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tradeshow equipment.", "label": "Tradeshow Equipment [Member]", "terseLabel": "Trade Show Equipment [Member]" } } }, "localname": "TradeshowEquipmentMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "hznp_TwentyTwentyFourSeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Twenty twenty four senior notes.", "label": "Twenty Twenty Four Senior Notes [Member]", "terseLabel": "2024 Senior Notes [Member]" } } }, "localname": "TwentyTwentyFourSeniorNotesMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwentyTwentySevenSeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Twenty twenty seven senior notes.", "label": "Twenty Twenty Seven Senior Notes [Member]", "terseLabel": "2027 Senior Notes [Member]" } } }, "localname": "TwentyTwentySevenSeniorNotesMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwentyTwentyThreeSeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Twenty Twenty Three Senior Notes.", "label": "Twenty Twenty Three Senior Notes [Member]", "terseLabel": "2023 Senior Notes [Member]" } } }, "localname": "TwentyTwentyThreeSeniorNotesMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwoThousandFourteenEmployeeSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand fourteen employee share purchase plan.", "label": "Two Thousand Fourteen Employee Share Purchase Plan [Member]", "terseLabel": "2014 ESPP [Member]" } } }, "localname": "TwoThousandFourteenEmployeeSharePurchasePlanMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwoThousandFourteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand fourteen equity incentive plan.", "label": "Two Thousand Fourteen Equity Incentive Plan [Member]", "terseLabel": "2014 EIP [Member]" } } }, "localname": "TwoThousandFourteenEquityIncentivePlanMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwoThousandFourteenNonEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand fourteen nonemployee stock purchase plan.", "label": "Two Thousand Fourteen Non Employee Stock Purchase Plan [Member]", "terseLabel": "2014 Non-Employee Plan [Member]" } } }, "localname": "TwoThousandFourteenNonEmployeeStockPurchasePlanMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_TwoThousandNineteenTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Nineteen Term Loan Facility.", "label": "Two Thousand Nineteen Term Loan Facility [Member]", "terseLabel": "2019 Term Loan Facility [Member]" } } }, "localname": "TwoThousandNineteenTermLoanFacilityMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_USFoodAndDrugAdministrationFDAApprovalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "U.S. food and drug administration (FDA) approval.", "label": "U S Food And Drug Administration F D A Approval [Member]", "terseLabel": "U.S. Food and Drug Administration (FDA) Approval [Member]" } } }, "localname": "USFoodAndDrugAdministrationFDAApprovalMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Underwritten public offering.", "label": "Underwritten Public Offering [Member]", "verboseLabel": "2018 Offering [Member]" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "hznp_UpfrontProgressAndMilestonePaymentsRelatedToLicenseAndCollaborationAgreements": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10130.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Upfront progress and milestone payments related to license and collaboration agreements.", "label": "Upfront Progress And Milestone Payments Related To License And Collaboration Agreements", "terseLabel": "Upfront and milestone payments related to license and collaboration agreements" } } }, "localname": "UpfrontProgressAndMilestonePaymentsRelatedToLicenseAndCollaborationAgreements", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "hznp_ValuationAllowancesAndReservesPaymentsRelatingToSalesInPriorYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Payments relating to sales in prior years.", "label": "Valuation Allowances And Reserves Payments Relating To Sales In Prior Year", "negatedLabel": "Payments relating to prior-year sales" } } }, "localname": "ValuationAllowancesAndReservesPaymentsRelatingToSalesInPriorYear", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "monetaryItemType" }, "hznp_VimovoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VIMOVO.", "label": "Vimovo [Member]", "terseLabel": "VIMOVO [Member]" } } }, "localname": "VimovoMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail" ], "xbrltype": "domainItemType" }, "hznp_WholesalerFeesAndCommercialRebatesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Wholesaler fees and commercial rebates.", "label": "Wholesaler Fees And Commercial Rebates [Member]", "terseLabel": "Wholesaler Fees and Commercial Rebates [Member]" } } }, "localname": "WholesalerFeesAndCommercialRebatesMember", "nsuri": "http://www.horizonoharma.com/20200331", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r145", "r217", "r221", "r377" ], "lang": { "en-US": { "role": { "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r142", "r217", "r219", "r374", "r375" ], "lang": { "en-US": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario Forecast [Member]", "terseLabel": "Scenario Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario Unspecified [Domain]", "terseLabel": "Scenario" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r144", "r217", "r220", "r376", "r382", "r383" ], "lang": { "en-US": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r189", "r333" ], "lang": { "en-US": { "role": { "label": "Statement Scenario [Axis]", "terseLabel": "Scenario" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_SubsidiariesMember": { "auth_ref": [ "r226", "r328", "r330" ], "lang": { "en-US": { "role": { "label": "Subsidiaries [Member]", "terseLabel": "Horizon Investment [Member]" } } }, "localname": "SubsidiariesMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r147", "r329" ], "lang": { "en-US": { "role": { "label": "Title Of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title Of Individual With Relationship To Entity [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Valuation And Qualifying Accounts Disclosure [Line Items]", "terseLabel": "Valuation And Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "label": "Valuation And Qualifying Accounts Disclosure [Table]", "terseLabel": "Valuation And Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities / Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpenses", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebates" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r16", "r35", "r148", "r149", "r218" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r19", "r20", "r58" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees Current", "terseLabel": "Consulting and professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r19", "r20", "r58" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties Current", "verboseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r52", "r173" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r75", "r76", "r77" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r74", "r77", "r78", "r287" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r36" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Adjustments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Ordinary shares withheld for payment of employees\u2019 withholding tax liability" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r228", "r230", "r260", "r261" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdvancesOnInventoryPurchases": { "auth_ref": [ "r71" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 10030.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.", "label": "Advances On Inventory Purchases", "terseLabel": "Advance payments for inventory" } } }, "localname": "AdvancesOnInventoryPurchases", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r230", "r255", "r259" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10050.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "negatedLabel": "Share-based compensation", "terseLabel": "Increase in share-based compensation expense", "verboseLabel": "Total share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForUncollectibleCustomersLiabilityForAcceptancesMember": { "auth_ref": [ "r119" ], "lang": { "en-US": { "role": { "documentation": "Allowance for portion expected to be uncollectible of receivable from customer for short-term negotiable time draft drawn on and accepted by financial institution (banker's acceptance).", "label": "Allowance For Uncollectible Customers Liability For Acceptances [Member]", "terseLabel": "Customer-related Accruals and Allowances [Member]" } } }, "localname": "AllowanceForUncollectibleCustomersLiabilityForAcceptancesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r108", "r314" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization Of Financing Costs And Discounts", "terseLabel": "Amortization of debt discount and deferred financing costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r108", "r161", "r167" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10030.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization Of Intangible Assets", "negatedLabel": "Intangible amortization expense", "terseLabel": "Amortization expense of developed technology" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Securities excluded from computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area Of Real Estate Property", "positiveLabel": "Office space", "terseLabel": "Approximate Square Feet", "verboseLabel": "Approximate square feet of office space" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r136", "r353", "r366" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r17", "r18", "r72" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Total assets at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r231", "r257" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2020PsusDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r291", "r292" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Bank Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Adjusted Base Rate [Member]" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r278", "r279" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date when the business acquisition agreement was executed, in CCYY-MM-DD format.", "label": "Business Acquisition Date Of Acquisition Agreement1", "terseLabel": "Business acquisition agreement date" } } }, "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition Percentage Of Voting Interests Acquired", "terseLabel": "Percentage of equity interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r276" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10090.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination Acquisition Related Costs", "negatedLabel": "Acquisition/divestiture-related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r283" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High", "terseLabel": "Maximum payment to be made upon attainment of milestones", "verboseLabel": "Milestone Payment" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r112", "r113", "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r49", "r379", "r380" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash on hand" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired From Acquisition", "terseLabel": "Cash acquired from acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r14", "r49", "r110" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r104", "r110", "r115" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r104", "r309" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r65", "r188", "r357", "r371" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r187", "r195" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Ordinary Shares [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Ordinary shares, nominal value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Ordinary shares, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Ordinary shares, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r34", "r207" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Ordinary shares, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r34" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at March 31, 2020 and December 31, 2019; 190,962,613 and 188,402,040 shares issued at March 31, 2020 and December 31, 2019, respectively, and 190,578,247 and 188,017,674 shares outstanding at March 31, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r81", "r83", "r84" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r131", "r132", "r304", "r305" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r131", "r132", "r304", "r305", "r378" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r131", "r132", "r304", "r305", "r378" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r131", "r132", "r304", "r305" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "positiveLabel": "Consolidated receivable/sales percentage to major customers", "terseLabel": "Gross Sales, Percentage", "verboseLabel": "Total Net Sales, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r131", "r132", "r304", "r305" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in Process [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration By Type [Axis]", "terseLabel": "Contingent Consideration by Type" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r63" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Long Term Notes Payable", "terseLabel": "Exchangeable notes, net" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r89" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10170.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost Of Goods And Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "verboseLabel": "Cost of Goods Sold [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.", "label": "Cumulative Effect On Retained Earnings Net Of Tax1", "terseLabel": "Cumulative effect adjustments from adoption of ASU 2016-02" } } }, "localname": "CumulativeEffectOnRetainedEarningsNetOfTax1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt Agreements" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt Instrument Annual Principal Payment", "terseLabel": "Convertible senior notes, principal payment" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r29", "r30", "r31", "r354", "r355", "r365" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Debt instrument variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r31", "r200", "r355", "r365" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail": { "order": 10010.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument Carrying Amount", "terseLabel": "Outstanding principal amount", "verboseLabel": "Total face value" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r199" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument Convertible Carrying Amount Of The Equity Component", "terseLabel": "Carrying amount of equity component" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument Convertible Conversion Price1", "verboseLabel": "Exchange price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r62", "r208", "r209", "r211" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument Convertible Conversion Ratio1", "terseLabel": "Debt Instrument, Convertible, Conversion Ratio (in shares per $1,000 principal amount)" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument Convertible Threshold Consecutive Trading Days1", "terseLabel": "Debt instrument consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger", "terseLabel": "Debt instrument convertible minimum percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument Convertible Threshold Trading Days", "terseLabel": "Debt instrument number of trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r303" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument Fair Value", "terseLabel": "Debt instrument, fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r63", "r362" ], "lang": { "en-US": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument Frequency Of Periodic Payment", "terseLabel": "Debt instrument, frequency of periodic payment" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r60", "r203", "r313" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument Interest Rate Effective Percentage", "terseLabel": "Debt instrument, effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r61", "r298" ], "lang": { "en-US": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "terseLabel": "Maturity date of debt instrument" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r63" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionDescription": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Description of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument Redemption Description", "terseLabel": "Debt instrument redemption description" } } }, "localname": "DebtInstrumentRedemptionDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument Redemption Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument Redemption Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument Redemption Price Percentage", "terseLabel": "Redemption price as percentage of aggregate principal amount" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed", "terseLabel": "Redemption amount as percentage of aggregate principal amount" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r63", "r118", "r208", "r210", "r211", "r212", "r312", "r313", "r315", "r364" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r312", "r315" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail": { "order": 10020.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument Unamortized Discount", "negatedLabel": "Debt discount", "verboseLabel": "Initial debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": { "auth_ref": [ "r222", "r223" ], "lang": { "en-US": { "role": { "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus And Profit Sharing Arrangement Individual Contract Type Of Deferred Compensation [Domain]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation" } } }, "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredBonusMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An contractual arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a bonus, as defined in the agreement, of the entity or portion thereof. Employer contributions may be discretionary or may be based on a fixed formula related to individual, group and entity-wide performance goals, compensation, or other factors. It is a form of incentive compensation to employees in addition to their regular salary and profit sharing.", "label": "Deferred Bonus [Member]", "terseLabel": "Cash Incentive Program [Member]" } } }, "localname": "DeferredBonusMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of commitment made to pay deferred cash remuneration.", "label": "Deferred Compensation Arrangement With Individual Cash Award Granted Amount", "terseLabel": "Bonus payable under cash bonus program" } } }, "localname": "DeferredCompensationArrangementWithIndividualCashAwardGrantedAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "auth_ref": [ "r223", "r230" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.", "label": "Deferred Compensation Arrangement With Individual Compensation Expense", "terseLabel": "Expense related to cash bonus program" } } }, "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r222", "r223" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Compensation Arrangement With Individual Excluding Share Based Payments And Postretirement Benefits By Type Of Deferred Compensation [Axis]", "terseLabel": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r53", "r314" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail": { "order": 10030.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Deferred Finance Costs Net", "negatedLabel": "Deferred financing fees" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetNoncurrent": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.", "label": "Deferred Tax Assets Net Noncurrent", "terseLabel": "Deferred tax assets, net" } } }, "localname": "DeferredTaxAssetsNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r264", "r271", "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards Domestic", "terseLabel": "Federal net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r264", "r271", "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards State And Local", "terseLabel": "State net operating losses" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r265", "r267", "r268" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities Noncurrent", "terseLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r108", "r171" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10070.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "negatedLabel": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r108", "r134" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Share-Based and Long-Term Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disposal group that is not classified as discontinued operations.", "label": "Disposal Group Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Not Discontinued Operations [Member]" } } }, "localname": "DisposalGroupNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Groups Including Discontinued Operations Name [Domain]", "terseLabel": "Disposal Group Name" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per ordinary share\u2014basic and diluted", "verboseLabel": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share Basic And Diluted [Abstract]", "terseLabel": "Basic and diluted net loss per share calculation:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r309" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "terseLabel": "Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Payroll-related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Pre-tax unrecognized compensation expense for all unvested share-based awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r294", "r295", "r296", "r301" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r294", "r301" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r224", "r225", "r227", "r295", "r335" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r294", "r295", "r297", "r298", "r302" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r224", "r225", "r227", "r295", "r336" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r224", "r225", "r227", "r295", "r337" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r224", "r225", "r227", "r295", "r338" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r300", "r302" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value Measurements, Recurring Basis [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r166" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail": { "order": 10020.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 10060.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite Lived Intangible Assets Amortization Expense After Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 10010.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year", "terseLabel": "2020 (April to December)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r168" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 10050.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite Lived Intangible Assets Amortization Expense Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r168" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 10040.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite Lived Intangible Assets Amortization Expense Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r168" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 10030.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite Lived Intangible Assets Amortization Expense Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r168" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": 10020.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite Lived Intangible Assets Amortization Expense Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r162", "r164", "r166", "r169", "r339" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r166", "r339" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail": { "order": 10010.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Gross", "terseLabel": "Cost Basis" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r162", "r165" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r166" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net Book Value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finitelived Intangible Assets Acquired1", "terseLabel": "Capitalized payments of intangible assets" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.", "label": "Foreign Currency Exchange Rate Translation1", "terseLabel": "Currency exchange rate" } } }, "localname": "ForeignCurrencyExchangeRateTranslation1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r306", "r307", "r308" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10150.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10100.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain Loss Before Tax", "terseLabel": "Foreign exchange gain (loss)", "verboseLabel": "Foreign exchange loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r108" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain Loss On Disposition Of Assets1", "totalLabel": "Loss on sale of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r108", "r204", "r205" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gains Losses On Extinguishment Of Debt", "negatedLabel": "Loss on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r155", "r156" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill And Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill And Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillChangeInGoodwillAllocationDescription": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Description of change in allocation of goodwill by reportable segment.", "label": "Goodwill Change In Goodwill Allocation Description", "terseLabel": "Change in goodwill allocation, description" } } }, "localname": "GoodwillChangeInGoodwillAllocationDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r157", "r158" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill Gross", "terseLabel": "Goodwill, gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r157", "r158" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill Impaired Accumulated Impairment Loss", "terseLabel": "Accumulated goodwill impairment losses" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill Period Increase Decrease", "terseLabel": "Increase (decrease) in allocation of goodwill" } } }, "localname": "GoodwillPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r88" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10120.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r86", "r122", "r352", "r358", "r373" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Loss before benefit for income taxes", "verboseLabel": "Loss before benefit for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxesBenefitForIncomeTaxesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Axis]", "terseLabel": "Disposal Group Name" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r11", "r12", "r177", "r178" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]", "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r117", "r135", "r274" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10050.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "negatedLabel": "Decrease in income tax benefit", "negatedTerseLabel": "Benefit for income taxes", "terseLabel": "Benefit for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxesBenefitForIncomeTaxesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid Net", "terseLabel": "Cash paid for income taxes, net of refunds received" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r107" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r107" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r107" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase Decrease In Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r107" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Contract With Customer Liability", "terseLabel": "Deferred revenues" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r107" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase Decrease In Deferred Income Taxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent": { "auth_ref": [ "r107" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in intangible assets (for example patents and licenses).", "label": "Increase Decrease In Intangible Assets Current", "negatedLabel": "Write off in net book value" } } }, "localname": "IncreaseDecreaseInIntangibleAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r107" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r107" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase Decrease In Other Operating Capital Net", "negatedLabel": "Other non-current assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r107" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r360" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10060.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income Expense Net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10080.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income Expense Nonoperating Net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r102", "r105", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r20", "r21", "r58" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10060.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r41", "r153" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail": { "order": 10030.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory Finished Goods Net Of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r15", "r70", "r152" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10270.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventories, net", "totalLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r43", "r153" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail": { "order": 10010.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory Raw Materials Net Of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r42", "r153" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail": { "order": 10020.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory Work In Process Net Of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.", "label": "Lease Expiration Date1", "terseLabel": "Lease Expiry Date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters And Contingencies [Text Block]", "terseLabel": "Legal Proceedings" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOfficeSpaceLeaseAgreementsInPlaceForRealPropertiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of Operating Lease Liabilities Recorded on the Balance Sheet" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r324" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Operating Lease liabilities,Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r324" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Operating Lease liabilities, Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r324" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "Operating Lease liabilities, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r324" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "Operating Lease liabilities, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r324" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "Operating Lease liabilities, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r324" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "Operating Lease liabilities, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r324" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Operating Lease liabilities, Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee Operating Leases [Text Block]", "terseLabel": "Lease Obligations" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r40", "r356", "r369" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and shareholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities Fair Value Disclosure", "negatedLabel": "Total liabilities at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r23", "r24", "r25", "r31", "r32" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities Noncurrent [Abstract]", "terseLabel": "LONG-TERM LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Current Borrowing Capacity", "terseLabel": "Line of credit facility borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityDescription": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.", "label": "Line Of Credit Facility Description", "terseLabel": "Credit agreement, description" } } }, "localname": "LineOfCreditFacilityDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDescription": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "Description of the interest rate for the amounts borrowed under the credit facility, including the terms and the method for determining the interest rate (for example, fixed or variable, LIBOR plus a percentage, increasing rate, timing of interest rate resets, remarketing provisions).", "label": "Line Of Credit Facility Interest Rate Description", "terseLabel": "Interest rate description" } } }, "localname": "LineOfCreditFacilityInterestRateDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "Aggregate principal amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate L I B O R [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r31", "r201", "r355", "r367" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt", "totalLabel": "Total long-term debt and exchangeable notes" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r57" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail2": { "order": 10010.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Current", "negatedLabel": "Less: long-term debt\u2014current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail2": { "order": 10020.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long Term Debt Noncurrent", "terseLabel": "Long-term debt and exchangeable notes, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.", "label": "Long Term Debt Percentage Bearing Variable Interest Rate", "terseLabel": "Debt instrument, variable interest rate" } } }, "localname": "LongTermDebtPercentageBearingVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long Term Purchase Commitment Amount", "terseLabel": "Minimum binding purchase commitment" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r63" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r63", "r198" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsOutstandingDebtBalancesParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r196", "r197" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfRemainingAggregatePotentialMilestonePaymentsPayableBasedOnAchievementOfNetSalesThresholdsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of another entity's patents that the entity has allegedly infringed.", "label": "Loss Contingency Patents Allegedly Infringed Number", "terseLabel": "Number of Patent covering infringement" } } }, "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLegalProceedingsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfErrorDomain": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of the error being corrected including when and how the error arose and the fact that the error had previously been considered immaterial.", "label": "Nature Of Error [Domain]", "terseLabel": "Nature of Error" } } }, "localname": "NatureOfErrorDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r104", "r106", "r109" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r79", "r82", "r87", "r109", "r127", "r359", "r372" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Numerator - net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxesBenefitForIncomeTaxesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non Us [Member]", "terseLabel": "Rest of World [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing And Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL NON-CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10070.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Total other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10130.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10010.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10060.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Operating loss", "verboseLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r318" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "verboseLabel": "Operating Lease liabilities, Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsScheduleOfOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Lease liability, noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r317" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r323", "r325" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r322", "r325" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r13", "r290" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation and Business Overview" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverview" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r19", "r20", "r21", "r58" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": { "order": 10070.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCapitalizedPropertyPlantAndEquipmentMember": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "All other long term capitalized assets related to property plant and equipment not otherwise previously categorized.", "label": "Other Capitalized Property Plant And Equipment [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherCapitalizedPropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r73", "r310" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10030.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax", "terseLabel": "Foreign currency translation adjustments", "verboseLabel": "Currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r80", "r83", "r85", "r207" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income Loss Net Of Tax", "totalLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "OTHER COMPREHENSIVE LOSS, NET OF TAX" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r291", "r293" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r64" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Long-term Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r92" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10160.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10110.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income Expense", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income Expense [Abstract]", "terseLabel": "OTHER EXPENSE, NET:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "stringItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables And Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r100" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Payment of employee withholding taxes relating to share-based awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r96", "r282" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments To Acquire Businesses Gross", "negatedLabel": "Payments for acquisition", "terseLabel": "Upfront cash payments" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r97" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments To Acquire Intangible Assets", "terseLabel": "Payments to acquire intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Stock Unit Awards [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2020PsusDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r231", "r257" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r17", "r47", "r48" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10280.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds From Convertible Debt", "verboseLabel": "Initial proceeds from convertible debt instrument" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r94" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail": { "order": 10010.0, "parentTag": "us-gaap_GainLossOnDispositionOfAssets1", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds From Divestiture Of Businesses", "terseLabel": "Cash proceeds" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsLossOnSaleOfAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r98" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Net proceeds from the issuance of ordinary shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds From Issuance Of Senior Long Term Debt", "terseLabel": "Net proceeds from senior notes" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds From Sale Of Intangible Assets", "terseLabel": "Rights sold for an upfront payment" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r98", "r258" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from the issuance of ordinary shares in connection with stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r79", "r82", "r103", "r136", "r141", "r284", "r285", "r286", "r288", "r289" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Additions", "terseLabel": "Purchase of building for consideration and transaction costs" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r52", "r174" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r51", "r172" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r27", "r28", "r174", "r370" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r50", "r116", "r174" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r27", "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r27", "r172" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Depreciation and amortization" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "durationItemType" }, "us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Information by type of error in the financial statements.", "label": "Quantifying Misstatement In Current Year Financial Statements By Nature Of Error [Axis]", "terseLabel": "Nature of Error" } } }, "localname": "QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureBasisOfPresentationAndBusinessOverviewAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Reconciliation From Segment Totals To Consolidated [Abstract]", "terseLabel": "Reconciling items:" } } }, "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r138", "r140" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation Of Operating Profit Loss From Segments To Consolidated [Text Block]", "terseLabel": "Summary of Reconciliations of Segment Operating Income" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r226", "r328", "r330", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments Of Long Term Debt", "terseLabel": "Repaid under credit agreement" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r101" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments Of Long Term Lines Of Credit", "negatedLabel": "Repayment of term loans" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments Of Secured Debt", "terseLabel": "Repayment of refinanced loans, amount" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r263", "r385" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10140.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research And Development In Process", "verboseLabel": "In-process research and development expense" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r14", "r26", "r110", "r115" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash And Cash Equivalents At Carrying Value", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r181", "r182", "r184", "r186" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10110.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring And Related Cost Incurred Cost", "negatedLabel": "Restructuring and realignment costs" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r108", "r180", "r183", "r185" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail": { "order": 10140.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Charges relating to discontinuation of Friedreich's ataxia program" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r213", "r368" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r216", "r217" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10160.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Total net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue From Contract With Customer [Member]", "terseLabel": "Sales Revenue [Member]" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue From External Customers By Geographic Areas Table [Text Block]", "terseLabel": "Summary of Net Sales Attributed to Geographic Sources" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The scenario under which facts represent plans as distinct from actual.", "label": "Scenario Plan [Member]", "terseLabel": "Step-down due to Leverage Ratio [Member]" } } }, "localname": "ScenarioPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Liabilities / Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedExpensesTables", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r278", "r279" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule Of Business Acquisitions By Acquisition [Table]", "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]", "terseLabel": "Benefit for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock": { "auth_ref": [ "r316", "r327" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of the investment in leveraged leases.", "label": "Schedule Of Components Of Leveraged Lease Investments Table [Text Block]", "terseLabel": "Schedule of Office Space Lease Agreements in Place for Real Properties" } } }, "localname": "ScheduleOfComponentsOfLeveragedLeaseInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureLeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r63", "r118", "r208", "r210", "r211", "r212", "r312", "r313", "r315", "r364" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule Of Debt Instruments [Text Block]", "terseLabel": "Outstanding Debt Balances" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r0", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r11", "r12", "r177", "r178" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Schedule Of Disposal Groups Including Discontinued Operations Income Statement Balance Sheet And Additional Disclosures [Text Block]", "terseLabel": "Gain (Loss) on Sale of Assets" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Basic and Diluted Net Loss per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r230", "r254", "r259" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Share-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Schedule Of Entity Wide Information Revenue From External Customers By Products And Services [Text Block]", "terseLabel": "Summary of Net Sales by Medicine for Reportable Segments" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r294", "r295" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Assets and Liabilities at Fair Value on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r162", "r165" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule Of Finite Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizableIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r162", "r165" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule Of Finite Lived Intangible Assets Table [Text Block]", "terseLabel": "Amortizable Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r159", "r160" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule Of Goodwill [Table]", "terseLabel": "Schedule Of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r159", "r160" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule Of Goodwill [Text Block]", "terseLabel": "Schedule of Goodwill for Reportable Segments" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r22", "r44", "r45", "r46" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule Of Inventory Current Table [Text Block]", "terseLabel": "Components of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureInventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule Of Nonvested Performance Based Units Activity Table [Text Block]", "terseLabel": "Summary of Performance Stock Unit Awards (PSUs) Activity" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule Of Other Current Assets Table [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r52", "r174" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block]", "terseLabel": "Schedule of Gross Sales to Customers Included in Reportable Segments and All Other Customers as a Group" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r133", "r136", "r137", "r139", "r159" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule Of Segment Reporting Information By Segment [Table]", "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r231", "r257" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2020PsusDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Summary of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r236", "r249", "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]", "terseLabel": "Estimated Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segment [Domain]", "terseLabel": "Segments" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment and Other Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationScheduleOfGrossSalesToCustomersIncludedInReportableSegmentsAndAllOtherCustomersAsGroupDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesAttributedToGeographicSourcesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfNetSalesByMedicineForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationOperatingIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting Information Operating Income Loss [Abstract]", "terseLabel": "Segment operating income:" } } }, "localname": "SegmentReportingInformationOperatingIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r90", "r151" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD": { "order": 10150.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling General And Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r93" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorLongTermNotes": { "auth_ref": [ "r63" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Long Term Notes", "positiveLabel": "Senior notes", "terseLabel": "Senior notes", "verboseLabel": "Long-term debt, net" } } }, "localname": "SeniorLongTermNotes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreements2027SeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsExchangeableSeniorNotesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r107" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Equity-settled share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Number of Units, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant-Date Fair Value Per Unit, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Number of Units, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant-Date Fair Value Per Unit, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Number of Units, Outstanding Ending Balance", "periodStartLabel": "Number of Units, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant-Date Fair Value Per Unit, Outstanding Ending Balance", "periodStartLabel": "Weighted Average Grant-Date Fair Value Per Unit, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Number of Units, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r247" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant-Date Fair Value Per Unit, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2020PsusDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "verboseLabel": "Risk free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2020PsusDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2020PsusDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r237", "r239" ], "lang": { "en-US": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number", "verboseLabel": "PSUs outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized", "terseLabel": "Increase to number of ordinary shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Common stock shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Common stock shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Options, Exercisable as of March 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable as of March 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period", "negatedLabel": "Options, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Options, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r238", "r257" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Options, Outstanding Ending Balance", "periodStartLabel": "Options, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r229", "r235" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfRestrictedStockUnitActivityDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2020PsusDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche One [Member]", "terseLabel": "Relative TSR PSUs [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Two [Member]", "terseLabel": "Net Sales PSUs [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Valuation date stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfSignificantValuationAssumptionsRelatedTo2020PsusDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage", "terseLabel": "Percentage of outstanding PSU award vesting amount range" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Stock options contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Aggregate Intrinsic Value, Exercisable as of March 31, 2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Weighted Average Contractual Term Remaining (in years) Exercisable as of March 31,2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted Average Contractual Term Remaining (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares Issued", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software And Software Development Costs [Member]", "terseLabel": "Software [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDepreciationAndAmortizationPeriodsForPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r136", "r159", "r176", "r182", "r186", "r374" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Statement Business Segments [Axis]", "terseLabel": "Segments" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillForReportableSegmentsDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSegmentAndOtherInformationSummaryOfReconciliationsOfSegmentOperatingIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r68", "r207" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Stock Compensation Plan [Member]", "terseLabel": "Equity Awards [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r112", "r113", "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued1", "terseLabel": "Transaction costs related to issuance of ordinary shares included in accrued expenses" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r33", "r34", "r207", "r213" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of ordinary shares - public offering, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r207", "r213" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period Shares Restricted Stock Award Gross", "terseLabel": "Issuance of ordinary shares in conjunction with vesting of restricted stock units, performance stock units and stock option exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r33", "r34", "r207", "r213", "r241" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Options, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r33", "r34", "r207", "r213" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of ordinary shares - public offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r33", "r34", "r207", "r213" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period Value Restricted Stock Award Gross", "terseLabel": "Issuance of ordinary shares in conjunction with vesting of restricted stock units, performance stock units and stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r34", "r38", "r39", "r150" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "SHAREHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r334" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.", "label": "Subsidiary Of Limited Liability Company Or Limited Partnership Ownership Interest", "terseLabel": "Cut off percentage for defining limited liability subsidiaries, portion of capital stock held maximum" } } }, "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r270" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "Federal tax credits" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAcquisitionsDivestituresAndOtherArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r69", "r214" ], "lang": { "en-US": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock Common Shares", "terseLabel": "Treasury stock, ordinary shares" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r67", "r214" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r67", "r214", "r215" ], "calculation": { "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock Value", "negatedLabel": "Treasury stock, 384,366 ordinary shares at March 31, 2020 and December 31, 2019" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesAdjustments": { "auth_ref": [ "r120" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.", "label": "Valuation Allowances And Reserves Adjustments", "terseLabel": "Adjustments relating to prior-year sales" } } }, "localname": "ValuationAllowancesAndReservesAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r120" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "Valuation Allowances And Reserves Balance", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Total customer-related accruals and allowances" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r120" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "Valuation Allowances And Reserves Charged To Cost And Expense", "terseLabel": "Current provisions relating to sales" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "Valuation Allowances And Reserves Deductions", "negatedLabel": "Payments relating to sales" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "Valuation Allowances And Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "Valuation Allowances And Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebates", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfAccruedTradeDiscountsAndRebatesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesScheduleOfCustomerRelatedAccrualsAndAllowancesDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureAccruedTradeDiscountsAndRebatesTables" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureDebtAgreementsTermLoanFacilityAndRevolvingCreditFacilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansAdditionalInformationDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureShareBasedAndLongTermIncentivePlansSummaryOfPerformanceStockUnitAwardsActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted average ordinary shares outstanding\u2014basic and diluted", "verboseLabel": "Denominator - weighted average ordinary shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.horizonoharma.com/20200331/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetail", "http://www.horizonoharma.com/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnauditedUSD" ], "xbrltype": "sharesItemType" } }, "unitCount": 14 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 1.N)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e30840-122693" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r13": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31928-109318" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84165051&loc=d3e45424-112738" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918631-209977" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=118948374&loc=SL77920254-209983" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r334": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611443-123010" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r386": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r387": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r388": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r389": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r391": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" } }, "version": "2.1" }